Hu Y F, Huang Y H, Luo W, Chen M X, Zhang J, Gou F
Department of Oncology, Affiliated Hospital of Guizhou Medical University/Department of Lymphoma, Guizhou Cancer Hospital,Gui Yang 550001,China.
Zhonghua Yi Xue Za Zhi. 2019 Dec 24;99(48):3792-3796. doi: 10.3760/cma.j.issn.0376-2491.2019.48.007.
To analyze the clinical characteristics and prognostic factors of patients with Hodgkin's lymphoma(HL). The clinical data of HL patients who were newly treated in Guizhou Cancer Hospital from August 2007 to March 2019 was retrospectively collected, and the efficacy and prognostic factors were analyzed. The clinical data of a total of 222 patients were analyzed in this study. The 5-year progression-free survival (PFS) and overall survival (OS)rate of them were 82.8% and 81.3%, respectively. The 5-year PFS rate and OS rate of early (stage Ⅰ-Ⅱ) HL were 87.3% and 86.1%, respectively, and the 5-year PFS rate and OS rate of progressive (stage Ⅲ-Ⅳ) HL were 77.9% and 76.3%, respectively. Among the 118 patients with early Hodgkin's lymphoma, the complete remission(CR) rate of chemotherapy alone was 55.6%(15/27), and chemotherapy plus radiotherapy was 86.8% (79/91), the difference between which was statistically significant (0.05). Compared with chemotherapy plus radiotherapy in early stage patients, 5-year PFS (93.0%) and 5-year OS (92.0%) rate in patients with chemotherapy plus radiotherapy were better than those with chemotherapy alone which were 63.7% and 62.1%, respectively. Multivariate analysis showed that age, LDH, ABVD cycle number and chemoradiotherapy were independent prognostic factors for 5-year OS and PFS rate in HL patients. The adverse reactions were increased level Ⅰ-Ⅱ aminotransferase with an incidence of 47.7% (106/222), decreased level Ⅰ-Ⅱ neutrophils with an absolute value of 54.1% (120/222), and decreased level Ⅲ-Ⅳ neutrophils with an absolute value of 45.9% (102/222). No adverse cardiac and pulmonary reactions or secondary tumors associated with chemotherapy was found in all patients. HL is a type of malignant tumor with good prognosis, and the short-term and long-term efficacy of chemotherapy combined with radiotherapy in early patients is better than that of chemotherapy alone. Age, LDH, ABVD cycle number and chemoradiotherapy are associated with prognosis in patients with Hodgkin's lymphoma. Adverse reactions can be tolerated.
分析霍奇金淋巴瘤（HL）患者的临床特征及预后因素。回顾性收集2007年8月至2019年3月在贵州肿瘤医院初治的HL患者的临床资料，并分析其疗效及预后因素。本研究共分析了222例患者的临床资料。他们的5年无进展生存率（PFS）和总生存率（OS）分别为82.8%和81.3%。早期（Ⅰ - Ⅱ期）HL的5年PFS率和OS率分别为87.3%和86.1%，进展期（Ⅲ - Ⅳ期）HL的5年PFS率和OS率分别为77.9%和76.3%。在118例早期霍奇金淋巴瘤患者中，单纯化疗的完全缓解（CR）率为55.6%（15/27），化疗加放疗为86.8%（79/91），两者差异有统计学意义（P<0.05）。与早期患者单纯化疗相比，化疗加放疗患者的5年PFS率（93.0%）和5年OS率（92.0%）优于单纯化疗患者，分别为63.7%和62.1%。多因素分析显示，年龄、乳酸脱氢酶（LDH）、ABVD方案化疗周期数及放化疗是HL患者5年OS率和PFS率的独立预后因素。不良反应为Ⅰ - Ⅱ级转氨酶升高，发生率为47.7%（106/222），Ⅰ - Ⅱ级中性粒细胞减少，绝对值为54.1%（120/222），Ⅲ - Ⅳ级中性粒细胞减少，绝对值为45.9%（102/222）。所有患者均未发现与化疗相关的心脏和肺部不良反应或继发性肿瘤。HL是一种预后良好的恶性肿瘤，早期患者化疗联合放疗的短期和长期疗效优于单纯化疗。年龄、LDH、ABVD方案化疗周期数及放化疗与霍奇金淋巴瘤患者的预后相关。不良反应可耐受。
